The tumor subtype based on ER, PR, and HER2 status has been validated in independent data set with significant differences in their clinical features even in Asian and European, early and metastatic breast cancer patients suggesting the robust classification[7–10]. The gene discussed is ERBB2; the disease is neoplasm.